OrthoPediatrics (NASDAQ:KIDS) CEO David Bailey Sells 19,535 Shares of Stock

OrthoPediatrics Corp. (NASDAQ:KIDS) CEO David Bailey sold 19,535 shares of OrthoPediatrics stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $17.25, for a total transaction of $336,978.75. Following the completion of the transaction, the chief executive officer owned 298,020 shares in the company, valued at approximately $5,140,845. This trade represents a 6.15% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

OrthoPediatrics Price Performance

Shares of NASDAQ:KIDS opened at $17.21 on Wednesday. OrthoPediatrics Corp. has a one year low of $15.28 and a one year high of $26.40. The stock has a fifty day moving average of $17.71 and a 200-day moving average of $17.94. The company has a market capitalization of $435.07 million, a PE ratio of -10.18 and a beta of 1.07. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.65 and a current ratio of 5.55.

OrthoPediatrics (NASDAQ:KIDS) last issued its earnings results on Thursday, February 26th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.11. OrthoPediatrics had a negative return on equity of 6.70% and a negative net margin of 16.77%.The business had revenue of $61.61 million for the quarter, compared to analysts’ expectations of $61.27 million. As a group, equities analysts anticipate that OrthoPediatrics Corp. will post -0.93 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have commented on KIDS. TD Cowen raised shares of OrthoPediatrics to a “strong-buy” rating in a research note on Tuesday, January 27th. Truist Financial boosted their price target on shares of OrthoPediatrics from $19.00 to $20.00 and gave the company a “hold” rating in a report on Monday, March 2nd. Weiss Ratings restated a “sell (e+)” rating on shares of OrthoPediatrics in a research report on Thursday, January 22nd. Wall Street Zen raised shares of OrthoPediatrics from a “sell” rating to a “hold” rating in a research note on Saturday, March 7th. Finally, Canaccord Genuity Group assumed coverage on shares of OrthoPediatrics in a research report on Wednesday, December 10th. They set a “buy” rating and a $24.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $24.67.

Hedge Funds Weigh In On OrthoPediatrics

Institutional investors and hedge funds have recently bought and sold shares of the business. Invesco Ltd. lifted its position in shares of OrthoPediatrics by 14.5% in the fourth quarter. Invesco Ltd. now owns 39,002 shares of the company’s stock worth $693,000 after purchasing an additional 4,925 shares in the last quarter. XTX Topco Ltd purchased a new position in OrthoPediatrics during the fourth quarter valued at approximately $188,000. Tudor Investment Corp ET AL grew its position in OrthoPediatrics by 59.3% during the fourth quarter. Tudor Investment Corp ET AL now owns 112,996 shares of the company’s stock valued at $2,007,000 after purchasing an additional 42,061 shares in the last quarter. Millennium Management LLC increased its stake in OrthoPediatrics by 48.0% in the 4th quarter. Millennium Management LLC now owns 1,396,495 shares of the company’s stock valued at $24,802,000 after buying an additional 452,840 shares during the period. Finally, Engineers Gate Manager LP purchased a new stake in OrthoPediatrics in the 4th quarter worth approximately $226,000. Hedge funds and other institutional investors own 69.05% of the company’s stock.

Trending Headlines about OrthoPediatrics

Here are the key news stories impacting OrthoPediatrics this week:

• Negative Sentiment: CEO David R. Bailey sold 19,535 shares at an average price of $17.25 (≈$336,979); his direct stake fell ~6.15% to 298,020 shares. SEC Filing
• Negative Sentiment: CFO Fred Hite sold 12,993 shares at $17.25 (≈$224,129); his holding decreased ~4.47% to 277,477 shares. SEC Filing
• Negative Sentiment: General Counsel Daniel J. Gerritzen sold 8,614 shares at $17.25 (≈$148,592); his stake fell ~5.45% to 149,533 shares. SEC Filing
• Negative Sentiment: Insider Gregory A. Odle sold 8,433 shares at $17.25 (≈$145,469); his position declined ~4.30% to 187,735 shares. SEC Filing
• Negative Sentiment: Insider Joseph W. Hauser sold 8,596 shares at $17.25 (≈$148,281); his stake fell ~4.23% to 194,767 shares. SEC Filing

OrthoPediatrics Company Profile

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.